Lakshmi Reddy Palam, PhD
Assistant Research Professor of Pediatrics
- Phone
- (317) 274-0914
- Address
-
Joseph E. Walther Hall
980 W. Walnut St.
Indianapolis , IN 46202 - PubMed:
-
Link to PubMed
Bio
Dr. Lakshmi Reddy Palam received his bachelor’s degree from Nagarjuna University, India. Dr. Palam subsequently completed his master’s degree in Biotechnology from Bharathidasan University, India. Dr. Palam completed his Ph.D. degree in biochemistry and molecular biology from Biochemistry department in IU School of Medicine, Indianapolis. Dr. Palam received his research training in laboratory of Dr. Ronald Wek, where he studied mRNA translation regulation mechanisms involved in cellular integrated stress response (ISR). Dr. Palam further pursued postdoctoral fellowship in endocrinology division, medicine department, IU School of Medicine, Indianapolis, where he studied the role of ISR to drug resistance in pancreatic cancer. Dr. Palam is currently the Assistant Research Professor in Herman B Wells Center for Pediatric Research, Pediatrics department, IU School of Medicine.
Key Publications
https://www.ncbi.nlm.nih.gov/pmc/?term=palam+lr
https://scholar.google.com/citations?user=U-731LkAAAAJ&hl=en
| Year | Degree | Institution |
|---|---|---|
| 2012 | Postdoctoral Training | Indiana University School of Medicine |
| 2012 | PhD | Indiana University |
| 2002 | MSC | Bharathidasan University |
| 2000 | BSC | Andhra Loyola College |
Dr. Palam research interests include elucidating role of epigenetic factors and cooperating c-KIT mutations in myeloid malignancies. Briefly, epigenetic factors such as TET2, DNMT3a, and ASXL1 are shown to be frequently mutated in myeloid malignancies such as myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Epigenetic alterations in hematopoietic stem and progenitor cells were shown to cause myeloid skewing and results in myeloid malignancies. Dr. Palam’s recent findings that loss of Tet2, a key regulator of genomic DNA methylation content, causes hyper proliferation of myeloid derived mast cells via aberrant activation of PI3K signaling and accumulated oncogenic c-Myc protein. Dr. Palam interested in mechanisms how loss of these epigenetic factors TET2, DNMT3a and ASXL1 drive hematopoietic dysregulation and myeloid malignancies.